Publications by authors named "Mina Sedrak"

Using a modified Delphi process, we engaged 28 experts in clinical trials, geriatrics, and research translation to determine if there were consensus around what clinical endpoints should be used for trials evaluating the efficacy of interventions to prevent or treat multiple age-related conditions. Four focus groups developed themes. Statements related to those themes were circulated back to participants in a survey.

View Article and Find Full Text PDF

The central premise of this article is that a portion of the established relationships between social determinants of health and racial and ethnic disparities in cancer morbidity and mortality is mediated through differences in rates of biological aging processes. We further posit that using knowledge about aging could enable discovery and testing of new mechanism-based pharmaceutical and behavioral interventions ("gerotherapeutics") to differentially improve the health of cancer survivors from minority populations and reduce cancer disparities. These hypotheses are based on evidence that lifelong differences in adverse social determinants of health contribute to disparities in rates of biological aging ("social determinants of aging"), with individuals from minoritized groups experiencing accelerated aging (ie, a steeper slope or trajectory of biological aging over time relative to chronological age) more often than individuals from nonminoritized groups.

View Article and Find Full Text PDF
Article Synopsis
  • This study examined changes in brain surface gyrification in older breast cancer survivors 5-15 years after chemotherapy, comparing them to those who did not receive chemotherapy and healthy controls.
  • It involved neuropsychological testing and MRI analysis, with 10 participants from the chemotherapy group, 12 from the non-chemotherapy group, and 13 healthy controls.
  • Results indicated that chemotherapy survivors had increased gyrification in some brain regions but decreased in others, suggesting a link between altered brain structure and cognitive changes in these survivors.
View Article and Find Full Text PDF

Background: Sacituzumab govitecan (sacituzumab) emerged as an important agent in metastatic and locally recurrent HER2-negative breast cancer treatment. UGT1A1 polymorphisms have also been shown to predict sacituzumab toxicity.

Methods: In this retrospective study, we sought to evaluate the associations between UGT1A1 status, toxicity, and therapeutic outcomes in sacituzumab recipients with advanced breast cancer who underwent genotype testing for UGT1A1 alleles (N = 68).

View Article and Find Full Text PDF
Article Synopsis
  • Palbociclib is a common treatment for advanced breast cancer in older adults, but its safety and tolerability for those aged 70 and older is not well established based on current studies.
  • A phase 2 study was conducted with 90 participants (median age 74) to assess safety, finding that 75.6% experienced grade 3 or higher adverse events within six months, with the most common being neutropenia.
  • The study revealed that older participants (≥75 years) tended to have higher rates of early treatment discontinuations due to adverse events compared to younger older adults (70-74 years), indicating the need for further research on treatment delivery in this age group.
View Article and Find Full Text PDF

Purpose: This study aimed to assess whether physical functional decline in older women with early-stage breast cancer is driven by cancer, chemotherapy, or a combination of both.

Methods: We prospectively sampled three groups of women aged ≥ 65: 444 with early-stage breast cancer receiving chemotherapy (BC Chemo), 98 with early-stage breast cancer not receiving chemotherapy (BC Control), and 100 non-cancer controls (NC Control). Physical function was assessed at two timepoints (T1 [baseline] and T2 [3, 4, or 6 months]) using the Physical Functioning Subscale (PF-10) of the RAND 36-item Short Form.

View Article and Find Full Text PDF

Introduction: Older adults with cancer facing competing treatments must prioritize between various outcomes. This study assessed health outcome prioritization among older adults with cancer starting chemotherapy.

Methods: Secondary analysis of a randomized trial addressing vulnerabilities in older adults with cancer.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on older breast cancer survivors who had received chemotherapy, examining changes in their hippocampal volume and shape over a period of 5-15 years.
  • Participants were divided into three groups: those who had chemotherapy, those who did not, and healthy controls.
  • Results showed that survivors who underwent chemotherapy experienced a loss in hippocampal volume and shape changes, which might relate to cognitive changes observed in this population.
View Article and Find Full Text PDF

Purpose: Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a bioactive polyphenolic substance, may help ameliorate inflammation-related conditions including osteoarthritis and pain.

Methods: We conducted a multisite randomized placebo-controlled, double-blind pilot trial (Alliance A22_Pilot9) to evaluate the effects of nanoemulsion curcumin (NEC, 200 mg/day) in postmenopausal women experiencing AIIA for ≥ 3 months.

View Article and Find Full Text PDF

Purpose: To assess white matter microstructural changes in older long-term breast cancer survivors 5-15 years post-chemotherapy treatment.

Methods: Breast cancer survivors aged 65 years or older who underwent chemotherapy (C+) and who did not undergo chemotherapy (C-) and age- and sex-matched healthy controls (HC) were enrolled at time point 1 (TP1) and followed for 2 years for time point 2 (TP2). All participants underwent brain MRI with diffusion tensor images and neuropsychological (NP) testing with the NIH Toolbox Cognition Battery.

View Article and Find Full Text PDF

Background: Older women with breast cancer frequently experience toxicity-related hospitalizations during adjuvant chemotherapy. Although the geriatric assessment can identify those at risk, its use in clinic remains limited. One simple, low-cost marker of vulnerability in older persons is fall history.

View Article and Find Full Text PDF

Background: Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). A reported association of Asian ancestry with this event merits investigation to rule out potential confounding.

Methods: Subjects in this retrospective cohort were female patients with HER2 positive breast cancer, of Asian or non-Hispanic White ancestry, who initiated T-DM1 or T-DXd from January 2017 through October 2021.

View Article and Find Full Text PDF

Background: When treating older women with breast cancer, life expectancy is an important consideration. ASCO recommends calculating 10-year mortality probabilities to inform treatment decisions. One useful tool is the Schonberg index, which predicts risk-based all-cause 10-year mortality.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the feasibility of an 8-week telehealth exercise program for frail survivors of hematopoietic cell transplantation (HCT), highlighting the challenges of traditional rehabilitation access.
  • - 20 participants were divided into an exercise group and a control group, and results showed that over 95% completed the study assessments, while about 45% in the exercise group completed the majority of their sessions.
  • - Although the intervention met its feasibility goals, there were no significant improvements observed in physical performance measures such as handgrip strength and fatigue, indicating mixed results regarding its effectiveness.
View Article and Find Full Text PDF

Purpose: The purpose of this prospective longitudinal study was to evaluate the changes in brain surface gyrification in older long-term breast cancer survivors 5 to 15 years after chemotherapy treatment.

Methods: Older breast cancer survivors aged ≥ 65 years treated with chemotherapy (C+) or without chemotherapy (C-) 5-15 years prior and age & sex-matched healthy controls (HC) were recruited (time point 1 (TP1)) and followed up for 2 years (time point 2 (TP2)). Study assessments for both time points included neuropsychological (NP) testing with the NIH Toolbox cognition battery and cortical gyrification analysis based on brain MRI.

View Article and Find Full Text PDF

Purpose: Family caregivers play an integral role in caring for older adults with cancer. Few studies have examined older adults with cancer and their family caregivers as a unit in a relationship or a dyad. Dyad congruence, or consistency in perspective, is relevant to numerous aspects of living with cancer, including the decision to enroll in a cancer clinical trial.

View Article and Find Full Text PDF

Background: The expansion of hematopoietic stem cells carrying recurrent somatic mutations, termed clonal hematopoiesis (CH), is common in elderly individuals and is associated with increased risk of myeloid malignancy and all-cause mortality. Though chemotherapy is a known risk factor for developing CH, how myelosuppressive therapies affect the short-term dynamics of CH remains incompletely understood. Most studies have been limited by retrospective design, heterogeneous patient populations, varied techniques to identifying CH, and analysis of single timepoints.

View Article and Find Full Text PDF

Background: Hyperglycemia is recognized as a common adverse event for patients receiving alpelisib but has been little studied outside of clinical trials. We report the frequency of alpelisib-associated hyperglycemia in a real-world setting and evaluate proposed risk factors.

Patients And Methods: We retrospectively identified patients with PIK3CA-mutated, hormone receptor-positive, metastatic breast cancer who initiated treatment with alpelisib plus fulvestrant between August 2019 and December 2021.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted on early-stage breast cancer patients without diabetes who received dexamethasone alongside taxane chemotherapy from August 2017 to December 2019.
  • The research found that 67% of these patients experienced steroid-induced hyperglycemia (SIH), with significant glycemic fluctuations in those reaching glucose levels above 200 mg/dL.
  • Non-Hispanic White patients had a notably higher risk for developing SIH, and over 90% of patients saw their hyperglycemia resolve after treatment, with only a small number remaining hyperglycemic post-treatment.
View Article and Find Full Text PDF

Background: Chemotoxicity risk scores were developed to predict grade 3-5 chemotherapy toxicity in older women with early breast cancer. However, whether these toxicity risk scores are associated with clinically meaningful decline in patient health remains unknown.

Methods: In a prospective study of women aged 65 years and older with stage I-III breast cancer treated with chemotherapy, we assessed chemotoxicity risk using the Cancer and Aging Research Group-Breast Cancer (CARG-BC) score (categorized as low, intermediate, and high).

View Article and Find Full Text PDF

Introduction: Aging-related concerns can increase the risk of treatment toxicities among older adults considering adjuvant chemotherapy. We previously demonstrated that older adults with cancer who reported feeling older than their chronological age (i.e.

View Article and Find Full Text PDF
Article Synopsis
  • Many cancer patients are older adults (65+), but they are often not well-represented in clinical trials, leading to a lack of relevant data for treating this group.
  • Recommendations from a working group suggest designing trials specifically for older adults or including them in existing trials through various cohort methods to improve participation.
  • Key considerations for these trials include taking into account the varied fitness levels of older adults and incorporating geriatric assessments to ensure appropriate patient selection and trial integrity.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessioni5jet98br03ohj1dehgnavd99orm5eih): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once